Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects

CONCLUSION: SHEN26 demonstrated satisfactory safety and tolerability in healthy subjects, which supports the continued study of SHEN26 against SARS-CoV-2.TRIAL REGISTRATION: The trial is registered in ClinicalTrials.gov (CT. gov identifier: NCT05504746).PMID:38662639 | DOI:10.1080/13543784.2024.2347302

Source: Expert Opinion on Investigational Drugs - April 25, 2024 Category: Drugs & Pharmacology Authors: Cheng Sun Hao Liu Ziwei Ouyang Jie Ding Qin Zhang Hongjie Ma Dandan Xu Qian Zhang Renpeng Zhou Mingming Yang Wei Hu Source Type: research